Abstract
Phase II trials of combination chemotherapies with cis-platinum (100 mg/m2) plus adriamycin (30 mg/m2) plus mitomycin-C (8 mg/m2): PAM, cis-platinum (80 or 100 mg/m2) plus vindesine (3 mg/m2 ×3): PV, and cis-platinum (100 mg/m2) plus vindesine (3 mg/m2×2) plus mitomycin-C (8 mg/m2): PVM were carried out in advanced non-small cell lung cancer, and their responses and toxicities were studied.
No patients achieved complete response in PAM, PV, and PVM. Among the 30 evaluable cases treated with PAM, there were 11 partial responders (36.7%). Among the 20 evaluable cases treated with PV, there were 8 partial responders (40.0%). Among the 9 evaluable cases treated with PVM, there were 3 partial responders (33.3%). The toxic effects were evaluated in the first course of PAM, PV and PVM. Leukocytopenia was seen more in PAM than in PV and PVM (p<0.05). Thrombocytopenia was seen more in PAM and PVM than in PV (p<0.025).A fall in hemoglobin was seen more in PV than in PAM and PVM (p<0.05). There were few differences in nonhematologic toxicities between PAM, PV, and PVM.
From the above results, it should be said that there were few differences in responses and toxic effects other than hematologic toxicity between PAM, PV, and PVM.
